- Home
- WDC vs BIIB Comparison
WDC vs BIIB Comparison
Compare WDC & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WDC
- BIIB
- Stock Information
- Founded
- WDC 1970
- BIIB 1978
- Country
- WDC United States
- BIIB United States
- Employees
- WDC N/A
- BIIB N/A
- Industry
- WDC Electronic Components
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- WDC Technology
- BIIB Health Care
- Exchange
- WDC Nasdaq
- BIIB Nasdaq
- Market Cap
- WDC 26.3B
- BIIB 18.7B
- IPO Year
- WDC N/A
- BIIB 1991
- Fundamental
- Price
- WDC $102.33
- BIIB $143.85
- Analyst Decision
- WDC Buy
- BIIB Buy
- Analyst Count
- WDC 20
- BIIB 27
- Target Price
- WDC $83.95
- BIIB $188.09
- AVG Volume (30 Days)
- WDC 7.5M
- BIIB 1.5M
- Earning Date
- WDC 10-23-2025
- BIIB 10-29-2025
- Dividend Yield
- WDC 0.41%
- BIIB N/A
- EPS Growth
- WDC N/A
- BIIB 31.67
- EPS
- WDC 5.14
- BIIB 10.45
- Revenue
- WDC $9,520,000,000.00
- BIIB $9,997,000,000.00
- Revenue This Year
- WDC $17.11
- BIIB $2.00
- Revenue Next Year
- WDC $4.41
- BIIB N/A
- P/E Ratio
- WDC $21.93
- BIIB $13.86
- Revenue Growth
- WDC 50.70
- BIIB 3.36
- 52 Week Low
- WDC $28.83
- BIIB $110.04
- 52 Week High
- WDC $98.86
- BIIB $204.18
- Technical
- Relative Strength Index (RSI)
- WDC 89.17
- BIIB 57.77
- Support Level
- WDC $77.90
- BIIB $139.54
- Resistance Level
- WDC $82.32
- BIIB $150.28
- Average True Range (ATR)
- WDC 2.63
- BIIB 4.43
- MACD
- WDC 1.38
- BIIB 0.46
- Stochastic Oscillator
- WDC 94.47
- BIIB 62.26
About WDC Western Digital Corporation
Western Digital is a leading vertically integrated supplier of hard disk drives. The HDD market is a practical duopoly, with Western Digital and Seagate being the two largest players. Western Digital designs and manufactures its HDDs, with much of the manufacturing and workforce located in Asia. The primary consumers of HDDs are data centers.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.